We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues.
- Authors
Hoshi, Seiji; Yaginuma, Kei; Meguro, Satoru; Onagi, Akifumi; Matsuoka, Kanako; Hata, Junya; Sato, Yuichi; Akaihata, Hidenori; Kataoka, Masao; Ogawa, Soichiro; Uemura, Motohide; Kojima, Yoshiyuki
- Abstract
Theranostics (therapy + diagnosis) targeting prostate-specific membrane antigen (PSMA) is an emerging therapeutic modality that could alter treatment strategies for prostate cancer. Although PSMA-targeted radioligand therapy (PSMA-RLT) has a highly therapeutic effect on PSMA-positive tumor tissue, the efficacy of PSMA-RLT depends on PSMA expression. Moreover, predictors of treatment response other than PSMA expression are under investigation. Therefore, the optimal patient population for PSMA-RLT remains unclear. This review provides an overview of the current status of theranostics for prostate cancer, focusing on PSMA ligands. In addition, we summarize various findings regarding the efficacy and problems of PSMA-RLT and discuss the optimal patient for PSMA-RLT.
- Subjects
PROSTATE cancer patients; PROSTATE cancer; CANCER treatment; TREATMENT effectiveness; COMPANION diagnostics
- Publication
Current Oncology, 2023, Vol 30, Issue 8, p7286
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol30080529